| Autor: |
Madeline Ally, Michael A. Sugarman, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton, Thomas K. Karikari, Hugo J. Aparicio, Brandon Frank, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Irene Simkin, Lindsay A. Farrer, Gyungah R. Jun, Katherine W. Turk, Andrew E. Budson, Maureen K. O'Connor, Rhoda Au, Lee E. Goldstein, Neil W. Kowall, Ronald Killiany, Robert A. Stern, Thor D. Stein, Ann C. McKee, Wei Qiao Qiu, Jesse Mez, Michael L. Alosco |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 15, Iss 4, Pp n/a-n/a (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2352-8729 |
| DOI: |
10.1002/dad2.12492 |
| Popis: |
Abstract Introduction This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p‐tau)181+231. Methods Plasma samples were analyzed using Simoa platform for 567 participants spanning the AD continuum. Cognitive diagnosis, neuropsychological testing, and dementia severity were examined for cross‐sectional and longitudinal outcomes. Results Plasma GFAP discriminated AD dementia from normal cognition (adjusted mean difference = 0.90 standard deviation [SD]) and mild cognitive impairment (adjusted mean difference = 0.72 SD), and demonstrated superior discrimination compared to alternative plasma biomarkers. Higher GFAP was associated with worse dementia severity and worse performance on 11 of 12 neuropsychological tests. Longitudinally, GFAP predicted decline in memory, but did not predict conversion to mild cognitive impairment or dementia. Discussion Plasma GFAP was associated with clinical outcomes related to suspected AD and could be of assistance in a plasma biomarker panel to detect in vivo AD. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text